CHA VACCINE RESEARCH INSTITUTE CHA Vaccine Research Institute Share Price
Equities
A261780
KR7261780001
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,840 KRW | +0.52% |
|
+1.36% | -14.34% |
| Sales 2022 | 179M 130K 10.41M | Sales 2023 | 294M 214K 17.05M | Capitalization | 151B 110M 8.76B |
|---|---|---|---|---|---|
| Net income 2022 | -6.72B -4.88M -389M | Net income 2023 | -1.75B -1.27M -101M | EV / Sales 2022 | 544 x |
| Net cash position 2022 | 34.13B 24.81M 1.98B | Net cash position 2023 | 34.57B 25.13M 2B | EV / Sales 2023 | 396 x |
| P/E ratio 2022 |
-19.6
x | P/E ratio 2023 |
-85.6
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.32% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.52% | ||
| 1 week | +1.36% | ||
| Current month | -5.84% | ||
| 1 month | -7.46% | ||
| 3 months | -10.70% | ||
| 6 months | +1.79% | ||
| Current year | -14.34% |
1 week
4 775.00
4 990.00
1 month
4 400.005 660.00
Current year
4 400.006 100.00
1 year
4 100.007 660.00
3 years
4 100.0014 900.00
5 years
4 100.0014 900.00
10 years
4 100.0014 900.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jeong-Seon Yeom
CEO | Chief Executive Officer | 62 | 30/09/00 |
Jung-Ki Cho
PSD | President | 54 | 31/12/18 |
Seung-Rae Kim
AUD | Comptroller/Controller/Auditor | 66 | 31/08/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Min-Sik Park
BRD | Director/Board Member | 54 | 29/02/20 |
Jung-Jae Koh
BRD | Director/Board Member | 70 | 28/02/17 |
Dae-Gyu Oh
BRD | Director/Board Member | 71 | 28/02/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 4,840 | +0.52% | 110,693 |
| 25/04/24 | 4,815 | -2.33% | 142,932 |
| 24/04/24 | 4,930 | +0.20% | 159,771 |
| 23/04/24 | 4,920 | +3.25% | 223,116 |
| 22/04/24 | 4,765 | -0.21% | 338,356 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
CHA Vaccine Research Institute Co Ltd is a Korea-based company principally engaged in the vaccines and immunotherapy research business based on based on adjuvant platform technology. The Company is engaged in the research and development (R&D) of premium preventive vaccines, therapeutic vaccines and immunotherapies such as hepatitis B virus (HBV) vaccines, chronic HBV vaccines and others. The Company is also engaged in the vaccines distribution and licensing out services.
Calendar
09/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -14.34% | 94M | |
| -2.40% | 103B | |
| +1.79% | 95.28B | |
| +1.46% | 22.15B | |
| -15.35% | 21.02B | |
| -8.58% | 18.15B | |
| -41.01% | 16.73B | |
| -13.20% | 16.05B | |
| +4.22% | 13.68B | |
| +35.48% | 12.17B |
- Stock Market
- Equities
- A261780 Stock
